# EDGAR Filing Document

**Accession Number:** 0001427570
**File Stem:** 0001104659-25-072063
**Filing Date:** 2025-7
**Character Count:** 3895
**Document Hash:** a91bd489c93959cc1f0f64f46ac2066c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-072063.hdr.sgml**: 20250730

**ACCESSION NUMBER**: 0001104659-25-072063

**CONFORMED SUBMISSION TYPE**: 425

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250730

**DATE AS OF CHANGE**: 20250730

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ReShape Lifesciences Inc.
- **CENTRAL INDEX KEY:** 0001427570
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 425
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37897
- **FILM NUMBER:** 251165869

**BUSINESS ADDRESS:**
- **STREET 1:** 1001 CALLE AMANECER
- **CITY:** SAN CLEMENTE
- **STATE:** CA
- **ZIP:** 92673
- **BUSINESS PHONE:** 949-429-6680

**MAIL ADDRESS:**
- **STREET 1:** 1001 CALLE AMANECER
- **CITY:** SAN CLEMENTE
- **STATE:** CA
- **ZIP:** 92673

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OBALON THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20080220
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ReShape Lifesciences Inc.
- **CENTRAL INDEX KEY:** 0001427570
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 425

**BUSINESS ADDRESS:**
- **STREET 1:** 1001 CALLE AMANECER
- **CITY:** SAN CLEMENTE
- **STATE:** CA
- **ZIP:** 92673
- **BUSINESS PHONE:** 949-429-6680

**MAIL ADDRESS:**
- **STREET 1:** 1001 CALLE AMANECER
- **CITY:** SAN CLEMENTE
- **STATE:** CA
- **ZIP:** 92673

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OBALON THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20080220

**Filed by ReShape Lifesciences Inc.**

**pursuant to Rule 425 under the Securities Act of 1933**

**and deemed filed pursuant to Rule 14a-12**

**under the Securities Exchange Act of 1934**

**Subject Company: ReShape Lifesciences Inc.**

**Commission File No.: 001-37897**

![](tm2521354d6_425img001.jpg)

July 30, 2025

**—AN URGENT MESSAGE TO OUR SHAREHOLDERS—**

We are writing today to update you on ReShape's solicitation efforts with respect **to Proposal 2 (Approval of Proposed Asset Sale)** and **Proposal 3 (Approval of Proposed Charter Amendment)**. As we have previously communicated, we adjourned ReShape's Special Meeting of Stockholders in connection with our transaction with Vyome Therapeutics, Inc. to August 7, 2025, to allow more time to approve Proposals 2 and 3, each of which requires support from a majority of the outstanding shares.

**Your vote is important, no matter how many or how few shares you may own**. These proposals will allow ReShape to take the next step in its evolution by focusing on advancing the development of the combined company's immune-inflammatory assets and identifying additional opportunities between the world-class Indian innovation corridor and the U.S. Market.

**Failing to vote will have the same effect as a vote <u>against</u> Proposals 2 and 3.**

**We urge you to cast your vote TODAY.** To ensure that your vote is received in time, we encourage you to vote electronically--by telephone or via the Internet--by following the simple instructions on the enclosed proxy card or voting instruction form. If you have received this letter by email, you may simply click the VOTE NOW button in the accompanying email.

We appreciate your continued investment in ReShape.

Regards,

Paul F. Hickey

Chief Executive Officer

***TIME IS SHORT AND YOUR VOTE IS IMPORTANT!***

If you have any questions, or need assistance in voting

your shares, please call our proxy solicitor,

**INNISFREE M&A INCORPORATED**

**TOLL-FREE, at 1-877-750-8310 (from the U.S. and Canada) <br> or +1-412-232-3651 (from other locations).**